Venezuela Spanish Labeling and IFU 2026: Destination Labeling Authorization

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Medical devices sold in Venezuela must carry labels, instructions for use and promotional material in Spanish. Circular N° DGSACS-008/2026 of July 9, 2026 further specifies that destination labeling must be duly authorized (etiquetado en destino debidamente autorizado) and that this requirement is enforced at customs nationwide.

GRZAN’s assessment: label compliance has moved forward from being a marketing requirement to being a customs clearance condition. Goods whose labeling has not been authorized may be stopped at clearance even where a valid sanitary registration and an import permit are held. The operational consequence is that labeling can no longer be treated as a downstream task handled by the importer after arrival; it has become an item on the critical path of the shipment itself.

This changes the order of work in a way that is easy to miss. A registration project typically treats artwork as a final step, prepared once the certificate number is known. If the labeling must be authorized before shipment, and shipment precedes or accompanies commercial launch, then artwork approval becomes a gate for goods flow and not only for registration. Projects that recognise this place artwork review at the same table as the dossier, with the same owner and the same deadline.

2. Legal basis

Regulation or documentReference numberPublication dateProvision or key point
Circular N° DGSACS-008/2026DGSACS-008/2026July 9, 2026Goods under legal regimes 3 and 12 and all consumer products for human use must present a valid sanitary registration, import permit and inventory, and ensure that destination labeling has been authorized
Circular N° DGSACS/0002/2025DGSACS/0002/2025October 28, 2025The renamed certificate title is applied uniformly at customs nationwide
Ley Orgánica de Salud (Health Organization Law)Gaceta Oficial N° 36.579November 11, 1998Legal basis for the regulation of health products

Scope statement: the requirements that labels and instructions be in Spanish and include the name and address of the registration holder, the registration number, the batch number, the expiry date, storage conditions, contraindications and warnings derive from industry material and are marked as a practical estimate.

3. Expert insights

Insight one: the term destination labeling reveals how the market actually operates.

Some imported products are packaged in the country of origin with labels in the language of that country; on arrival in Venezuela, Spanish labels are applied at destination, which is what destination labeling means. Circular DGSACS-008/2026 requires that this application be authorized, and unauthorized self-labeling is no longer accepted. The change bears directly on supply chain models that depend on labeling after arrival, because the shipment now waits for an authorization rather than for a warehouse slot.

For the manufacturer this shifts responsibility upstream. The party that prints the artwork, whether it is the manufacturer or a contract packager, must work from an approved version rather than from a translation prepared locally, and the approved version must be traceable to a specific authorization. A relabeling operation performed in a warehouse without that traceability is precisely the practice the circular addresses, and it is now a customs risk rather than a documentation formality.

Insight two: among the label elements, the holder name and address and the registration number are the two most error-prone.

The holder name and address must match the certificate exactly, and the registration number must be the valid certificate number. Cases have occurred in which a physical model code differing from the certificate by a single letter led to detention by customs. Character-level consistency between label and certificate is a hard condition for clearance, and it is checked by people who compare documents rather than by people who understand the product.

Two further elements are routinely incomplete. The batch number and expiry date must be applied in a way that remains legible for the life of the product, and storage conditions must be stated in terms the user can act on. A label that satisfies the reviewer on content but fails on legibility or on completeness at the point of use is still a defective label, and the defect surfaces in the market rather than in the file.

Insight three: the translation quality of the instructions for use is a patient safety issue.

Translation errors can lead to misuse, with consequences that include complaints, recalls and liability claims. The Venezuelan requirement is not merely that a Spanish version exists, but that its content is accurate and includes the mandatory information required by regulation. A literal translation of an English leaflet frequently preserves the words and loses the instruction, which is the failure mode that matters most for a device used by lay users at home.

Insight four: promotional material falls within the Spanish language requirement as well.

This point is often overlooked. Product catalogues, brochures and exhibition material aimed at the Venezuelan market are subject to the same language requirement and can create consistency problems with the label. A claim made in a brochure that does not appear in the instructions for use, or a model designation used in a catalogue that differs from the certificate, creates exposure that no one is monitoring because promotional material is not usually part of the registration file.

The practical control is to give the marketing team the approved label wording as a fixed reference and to require that any claim, model name or figure used externally can be traced to the instructions for use or the technical file. That single rule, applied before material is printed rather than after, prevents a class of problems that no amount of dossier work can repair once the goods are in the country.

4. Practical recommendations

  1. Complete labeling authorization before shipment, and abandon any sequence that plans to deal with it after arrival.
  2. Run a character-by-character check between label and certificate, covering product name, model, registration number, and holder name and address.
  3. Commission the instructions for use from a translator with a medical background, retain the review records, and confirm that the final version matches the intended use wording in the technical file.
  4. Include promotional material in the same checking process, so that catalogues, brochures and exhibition material do not contradict the label or the instructions.

5. Verification checklist

  • □ Destination labeling has been authorized before shipment
  • □ Model, registration number and holder information are character-consistent between label and certificate
  • □ The instructions for use are in Spanish and were translated by a translator with a medical background
  • □ The label includes batch number, expiry date, storage conditions, contraindications and warnings
  • □ Promotional material has been included in the consistency check

Regulatory information verified as of October 29, 2026.

For a product-specific feasibility assessment of Venezuela market entry, GRZAN’s regulatory team supports manufacturers, importers and authorized representatives with registration dossiers, conformity documentation and submissions to the Venezuelan health authority. Contact info@grzanglobal.com to discuss your project.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail